Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial

Thigpen, 2011, First-line therapy in ovarian cancer trials, Int J Gynecol Cancer, 21, 756, 10.1097/IGC.0b013e31821ce75d

Katsumata, 2009, Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial, Lancet, 374, 1331, 10.1016/S0140-6736(09)61157-0

Yedema, 1992, Use of serum tumor markers in the differential diagnosis between ovarian and colorectal adenocarcinomas, Tumour Biol, 13, 18, 10.1159/000217748

Jelliffe, 1973, Letter: creatinine clearance: bedside estimate, Ann Intern Med, 79, 604, 10.7326/0003-4819-79-4-604

Rustin, 2006, Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide, J Clin Oncol, 24, 45, 10.1200/JCO.2005.01.2757

Bookman, 2009, Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III Trial of the Gynecologic Cancer Intergroup, J Clin Oncol, 27, 1419, 10.1200/JCO.2008.19.1684

Jaaback, 2011, Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer, Cochrane Database Syst Rev, 11, 10.1002/14651858.CD005340.pub3

Burger, 2011, Incorporation of bevacizumab in the primary treatment of ovarian cancer, N Engl J Med, 365, 2473, 10.1056/NEJMoa1104390

duPont NC, Brady MF, Burger RA, et al. Prognostic significance of ethnicity and age in advanced stage ovarian cancer: an analysis of GOG 218. SGO Annual Meeting. 2013; abstract 54.

Fuh K, Shin J, Blansit K, et al. The treatment and survival differences of Asians versus whites with epithelial ovarian cancer. SGO Annual Meeting. 2013; abstract 53.

Kurman, 2010, The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory, Am J Surg Pathol, 34, 433, 10.1097/PAS.0b013e3181cf3d79

Anglesio, 2011, IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer, Clin Cancer Res, 17, 2538, 10.1158/1078-0432.CCR-10-3314

Behbakht, 2011, Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study, Gynecol Oncol, 123, 19, 10.1016/j.ygyno.2011.06.022

du Bois, 2003, A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer, J Natl Cancer Inst, 95, 1320, 10.1093/jnci/djg036

Ando, 2000, Multi-institutional validation study of carboplatin dosing formula using adjusted serum creatinine level, Clin Cancer Res, 6, 4733

Levey, 2006, Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate, Ann Intern Med, 145, 247, 10.7326/0003-4819-145-4-200608150-00004

Matsuo, 2009, Revised equations for estimated GFR from serum creatinine in Japan, Am J Kidney Dis, 53, 982, 10.1053/j.ajkd.2008.12.034

Pignata, 2013, Proc Am Soc Clin Oncol, 31